Enhancement of fibrinolysis and antagonism of antiplasmin by reversible plasmin inhibitors

Maxwell, Richard E.; Lewandowski, Vera; Nickel, Violet S.

doi:10.1016/0024-3205(65)90031-7

Cited by 7 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned, differ ent forms of plasminogen differ in r eactivity towards plasminogen activators (Wallen and Wiman 1973;Claeys et al 1973) and in their behavior towards E ACA in activator-induced fibrinolysis or caseinolysis (Thorsen et al 1972) . Contaminating inhibitors could also influence the results because the effects of plasma, serum or purified plasma inhibitors are potentiated in presence of EACA (Abiko and Iwamoto 1970 ;Egeblad 1966;Geratz 1973 ;Maxwell et al 1965). Fibrinogen preparations (Cohn Fraction I) are known to contain inhibitors of fibrinolysis (Mosesson an d Finlayson 1963).…”

Section: Discussionmentioning

confidence: 99%

Substrate Composition and the Effect of ε-Aminocaproic Acid on Tissue Plasminogen Activator and Urokinase-induced Fibrinolysis

Thorsen¹,

Astrup²

1974

Thromb Haemost

View full text Add to dashboard Cite

SummaryThe influence of variations in substrate composition on the biphasic pattern of inhibition by e-aminocaproic acid (EACA) of urokinase-induced fibrinolysis, first observed on bovine plasminogen-rich fibrin, was studied using a fibrin clot lysis time assay. Different species of fibrinogen and plasminogen or plasmin were used. Preparations of different degrees of purification were compared at varying concentrations. The behavior of urokinase was compared with that of a porcine tissue plasminogen activator. Variations in the conditions of the assay greatly influenced the results. The concentration of fibrinogen had a particularly marked influence. At increased fibrinogen concentrations the biphasic response of urokinase was enhanced and a weak biphasic effect was also produced by the tissue activator which usually yields a uniformly increasing inhibition curve. The phase of fibrinolysis enhancement produced by urokinase with genuine plasminogen substrates occurs at substrate concentrations and EACA levels present in patients treated with EACA. The observed variations may explain discordant findings reported by various investigators.

show abstract

Section: Discussionmentioning

confidence: 99%